Search Results
AHSCT vs. high-activity DMTs in MS treatment
The case for offering AHSCT as a first-line treatment for MS
Guidelines for aHSCT in MS
Early initiation of high-efficacy DMTs in MS
Repositioning HSCT in the MS treatment algorithm
Future studies on aHSCT for multiple sclerosis
The impact of MS treatments on PIRA
How Do I Choose an MS Treatment? | Decisions
Professor Basil Sharrack and Professor John Snowden - AHSCT and the management of MS
Early use of high-efficacy therapies in people with MS: What is holding us back? |MS Academy Webinar
AHSCT for highly active and rapidly evolving severe MS during the COVID-19 pandemic
Can A Stem Cell Transplant Stop Your MS?
